Cevahir ÇOBAN, İpek IŞILAK, Sebahat AKSARAY, Engin GÜVENER

Metisilin dirençli staphylococcus aureus'larda vankomisin ve teikoplanin duyarlılığının in vitro değerlendirilmesi

Metisilin dirençli Staphylococcus aureus (MRSA) suşlarının ortaya çıkmasıyla birlikte glikopeptid antibiyotiklerin yaygın olarak kullanımı da gündeme gelmiştir. Bu çalışmada Ankara Numune Hastanesi'nde çeşitli klinik örneklerden izole edilen 100 adet MRSA suşunun vankomisin ve teikoplanin duyarlılığı mikrodilüsyon yöntemi kullanılarak araştırıldı. Metisilin direncinin tespitinde l $mu$g'lık oksasilin diski kullanıldı. Her iki antibiyotiğin minimal inhibitor konsantrasyonları (MİK), mikrodilüsyon yöntemi ile NCCLS'in önerilerine göre tespit edildi. MİK90 değerleri kriter alındığında teikoplaninin etkinliğinin vankomisinden dört kat daha güçlü olduğu gözlendi. Bu nedenle, MRSA türlerinin neden olduğu infeksiyonlarda, teikoplaninin daha iyi bir alternatif olabileceği kanısına varıldı.

In vitro determination of sensitivity of vancomycin and teicoplanin in methicillin resistant staphylococcus aureus

At the presence of methicillin resistant Staphylococcus aureus (MRSA) infections; glycopeptide antibiotics are being used widely. In this study, vancomycin and teicoplanin sensitivity of 100 MRSA strains which were isolated from various clinical specimens in Ankara Numune Hospital, were investigated using microbroth dilution method. To detect the methicillin resistance standard 1 $mu$g disk of oxacillin was used. The minimum inhibitory concentration (MIC) of both antibiotics were detected by using microbroth dilution method according to the recommendations of NCCLS. Teicoplanin was observed four times more potent than vancomycin in terms of MIC90 values. For this reason, teicoplanin can be used as a good therapeutic alternative in infections caused by MRSA strains.

PDF

___

1-Campoli-Richards DM, Brogden RN, Faulds D. Teicoplanin: A review of its antibacterial activity, pharmacokinetic properties and therapeutic potential. Drugs t990; 40(3): 449-86.
2-Le Frock JL, Ristuccia AM, Ristuccia PA et al. Teicoplanin in the treatment of bone and joint infections. Europ J Surg t992; 567: 9- t3.
3-National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. NCCLS document M7-A3. Villanova. Pennsylvania; NCCLS: 1997.
4-Isenberg Henry D. Broth microdilution MC testing. Clinical microbiology procedures handbook, ASM, Washington DC, 1992; 5.2. t
5 Phillips G. Golledge CL. Vancomycin and teicoplanin: something old, something new. Med J Australia t992; t56: 53-8.
6-Janknegt R. Teicoplanin in perspective. A critical comparison with vancomycin. Pharmaceutisch Weekblad- Scientific Edition, Netherland; t99 t; t3(4): 153-60.
7-Keeny MT, Dulworth B. Comparative in vitro activity of teicoplanin and vancomycin against US teicoplanin clinical trial isolates of Gram positive cocci. Diag Microbiol Infecti Dis 199 t; t4 (t): 29-3 t.
8-Parenti F. Structure and mechanism of action of teicoplanin. J Hosp Inf. t986; 7 (Suppl A): 79-83.
9-Bezian MC, Ribou G, Masquelier B. In vitro activity of vancomycin and teicoplanin against gram positive cocci. Pathologie Bio1ogie, French, t992; 40 (5): 46t-5.
10-Shonekan D, Mildvan D, Handwerger S. Comparative in vitro activities of teicoplanin, daptomycin, ramoplanin, vancomycin and PD: t2739 t against blood isolates of Gram positive cocci. Antimicrobial Agents Chemother t992; 36 (7): t570-2.
11-Sloos JH, van de Klundert JAM, van Bowen CPA. Changing susceptibilities for glycopeptides in coagulase negative Staphylococcus. European Congress of Chemotherapy Scothland, Abstract Book, 1996; T t63.